Clinical Trials Logo

Neoplasms, Second Primary clinical trials

View clinical trials related to Neoplasms, Second Primary.

Filter by:

NCT ID: NCT06424210 Completed - Esophageal Cancer Clinical Trials

The Role of Surgery for Esophageal Cancer With Metastatic Disease (M1)

Start date: February 15, 2023
Phase:
Study type: Observational

Treatment of stage IV esophageal cancer is traditionally palliative, but treatment response is usually poor. The role of surgery in the treatment of advanced esophageal cancer remains controversial. We sought to determine whether surgical treatment followed by neoadjuvant chemoradiation therapy might provide survival benefits for these patients. A retrospective review of esophageal cancer patients with M1 disease treated at National Taiwan University Hospital was performed from April 2002 to June 2021. Patient demographics and cancer staging, treatment, and disease recurrence, and time of follow up were included for analysis. Univariate and multivariate analysis was performed for overall survival and progression-free survival analysis. Propensity score matching based on patient age and tumor staging characteristics was also performed for analysis.

NCT ID: NCT06423924 Not yet recruiting - Colorectal Cancer Clinical Trials

Second Primary Cancer and Early-onset Colorectal Cancer

Start date: May 11, 2024
Phase:
Study type: Observational

The objective of this study was to analyze the pathological factors influencing the occurrence and prognosis of SPC in CRC patients of varying ages and compare the differences in the patterns of SPC occurrence and prognosis among patients of different age groups.

NCT ID: NCT06410040 Active, not recruiting - Brain Metastases Clinical Trials

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

Start date: August 20, 2023
Phase:
Study type: Observational

This study was a retrospective observational study. The study included patients with non-small cell lung cancer with ALK-fusion brain metastases or meningeal metastases who received first-line and late-line treatment with the third-generation ALK TKI lorlatinib between June 2022 and June 2023. Data were collected from the electronic medical records database and hospital information system of many hospitals in Sichuan Province. Clinical pathology features including gender, age, ALK mutation status at diagnosis, and clinical stage at diagnosis were collected from the medical records. The physical condition assessed by ECOG-PS before the administration of lorlatinib was recorded. Information on anti-tumor therapy was obtained from the records, including dose and time of ALK-TKI therapy and tumor response, number of prior systemic therapy lines, drug regimen, efficacy, and whether local therapy such as radiotherapy and surgery had been received. In this study, the sample size is not limited, and information is collected according to the maximum number of patients. The study period was from 01 July 2023 to 30 June 2024.

NCT ID: NCT06376435 Not yet recruiting - Clinical trials for Cancer, Therapy-Related

A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in Concurrent/Sequential Radioimmunoinduced Thrombocytopenia

Start date: April 20, 2024
Phase:
Study type: Observational

The objective of this study was to observe and evaluate the efficacy and safety of hexapopal ethanolamine tablets in the treatment of synchronous/sequential radioimmunoinduced thrombocytopenia in the real world. The subjects of this study were patients with solid malignant tumors who had received radioimmunoinduced thrombocytopenia. This study will retrospectively and prospectively collect real-world data related to investigational drugs, and will observe 500 patients to observe the diagnosis and treatment pattern of radiochemo-induced thrombocytopenia. The study included a screening period (no more than one week) and a treatment period (at least two cycles).Participants meeting protocol inclusion criteria were defined as having platelet values < 100×109/L during radioimmunotherapy.

NCT ID: NCT06376344 Enrolling by invitation - Cancer Clinical Trials

The Effect of Tennis Ball on Balance and Quality of Life in Cancer Patients With Neuropathy.

Start date: April 28, 2024
Phase: N/A
Study type: Interventional

This research; It was aimed to evaluate the effect of myofascial release using a tennis ball on balance and quality of life in cancer patients who developed peripheral neuropathy.

NCT ID: NCT06367972 Recruiting - Clinical trials for OligoProgressive Metastatic Disease

A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)

Start date: June 6, 2024
Phase: Phase 2
Study type: Interventional

To find out if local consolidation therapy (such as radiation therapy with or without other local therapies such as surgery, ablation [the removal or destruction of a body part or tissue or its function], or embolization [a procedure that uses particles, such as tiny gelatin sponges or beads, to block a blood vessel]) to all progressive sites of disease can help to control the disease compared with next-line systemic therapy.

NCT ID: NCT06306924 Recruiting - Cancer Clinical Trials

UNC Metastatic Cancer Radiation Therapy Registry

Start date: April 21, 2024
Phase:
Study type: Observational

The purpose of this registry is to collect clinical data from participants attending UNC Hospitals who present with metastatic cancer and are evaluated to receive radiation therapy as part of their standard of care treatment. The goal of this study is to provide a foundation for studies designed to identify projects across the translational continuum related to metastatic cancer and radiation therapy treatment. The relevant clinical data will be linked to patient-reported outcomes (PROs) thus allowing for a unique and robust dataset. Ultimately, this registry will provide current and future studies with the ability to analyze the correlation of radiation therapy regimens with metastatic cancer outcomes.

NCT ID: NCT06291688 Recruiting - Cancer Clinical Trials

Applying Mobile Healthcare Education to Improve Cutaneous Self-care Capability

Start date: January 26, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical interventional study is to compare the efficacy of mobile healthcare education in two ways (game-based or text-based) to improve cutaneous self-care capability in cancer patients receiving EGFR-based target therapy. The main questions it aims to answer are: Impact of different mobile healthcare education ways on cutaneous self-care capability of patients Impact of different mobile healthcare education ways on learning motivation of patients towards cutaneous self-care knowledge and skills Participants will be randomly divided into two groups. Both groups will download a healthcare education application on their phone. One group will accept the education about the knowledge and self-care skills of cutaneous adverse drug reaction by playing game. In contrast, the other group will accept the same education content by reading text on the phone. Subjects will be asked to use the application at home for two weeks after giving consent to participate this study, and then completed questionnaire three times during study period. The timepoints of completing questionnaire are listed following: Baseline / pre-intervention test (after signing informed consent form, D1) First post-intervention test (after finishing intervention, D15) Second post-intervention test (D30) Researchers will compare game group and text group to see if game group has better performance on cutaneous self-care capability and learning motivation.

NCT ID: NCT06282874 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Start date: March 1, 2024
Phase: Phase 4
Study type: Interventional

This study is an investigator-initiated, prospective, open-label, single-arm, multicenter clinical trial aimed at exploring the antitumor activity of Lorlatinib in ALK-positive NSCLC patients with brain/ leptomeningeal metastases.

NCT ID: NCT06280612 Completed - Happiness Clinical Trials

The Effect of Live Cat and Simulation Cat Therapies on Oncology Patients

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

It is known that animals are good for humans physiologically and psychologically. Therefore, in this study, the effects of live cat and robotic cat therapies on the symptoms and happiness levels of oncology patients after chemotherapy were examined.